The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
|Articles|August 24, 2012
BREAKING: One-Year Delay on ICD-10 to October 2014 Finalized
Advertisement
The federal government has finalized a one-year delay in the compliance deadline for the nationwide conversion to ICD-10 code sets. The delay, first proposed in April, will move the compliance deadline to Oct. 1, 2014.
Read the full story:
Source: ModernHealthcare.com
HHS said the extra time would allow healthcare organizations—small organizations in particular—adequate time to get ready for the changeover.
Advertisement
Related to this article
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5